Effect of Disease Severity on the Performance of Cirrus Spectral-Domain OCT for Glaucoma Diagnosis

Effect of Disease Severity on the Performance of Cirrus Spectral-Domain OCT for Glaucoma Diagnosis

Author Leite, Mauro Toledo Autor UNIFESP Google Scholar
Zangwill, Linda M. Google Scholar
Weinreb, Robert N. Google Scholar
Rao, Harsha L. Google Scholar
Alencar, Luciana M. Google Scholar
Sample, Pamela A. Google Scholar
Medeiros, Felipe Andrade Autor UNIFESP Google Scholar
Institution Univ Calif San Diego
Universidade Federal de São Paulo (UNIFESP)
LV Prasad Eye Inst
Universidade de São Paulo (USP)
Abstract PURPOSE. To evaluate the effect of disease severity on the diagnostic accuracy of the Cirrus Optical Coherence Tomograph (Cirrus HD-OCT; Carl Zeiss Meditec, Inc., Dublin, CA) for glaucoma detection.METHODS. One hundred thirty-five glaucomatous eyes of 99 patients and 79 normal eyes of 47 control subjects were recruited from the longitudinal Diagnostic Innovations in Glaucoma Study (DIGS). the severity of the disease was graded based on the visual field index (VFI) from standard automated perimetry. Imaging of the retinal nerve fiber layer (RNFL) was obtained using the optic disc cube protocol available on the Cirrus HD-OCT. Pooled receiver operating characteristic (ROC) curves were initially obtained for each parameter of the Cirrus HD-OCT. the effect of disease severity on diagnostic performance was evaluated by fitting an ROC regression model, with VFI used as a covariate, and calculating the area under the ROC curve (AUCs) for different levels of disease severity.RESULTS. the largest pooled AUCs were for average thickness (0.892), inferior quadrant thickness (0.881), and superior quadrant thickness (0.874). Disease severity had a significant influence on the detection of glaucoma. for the average RNFL thickness parameter, AUCs were 0.962, 0.932, 0.886, and 0.822 for VFIs of 70%, 80%, 90%, and 100%, respectively.CONCLUSIONS. Disease severity had a significant effect on the diagnostic performance of the Cirrus HD-OCT and thus should be considered when interpreting results from this device and when considering the potential applications of this instrument for diagnosing glaucoma in the various clinical settings. (Invest Ophthalmol Vis Sci. 2010;51:4104-4109) DOI:10.1167/iovs.094716
Language English
Sponsor Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
National Eye Institute (NEI)
Alcon Laboratories Inc.
Allergan
Pfizer Inc.
Santen, Inc.
Grant number CAPES: BEX1327/09-7
National Eye Institute (NEI): EY08208
National Eye Institute (NEI): EY11008
Date 2010-08-01
Published in Investigative Ophthalmology & Visual Science. Rockville: Assoc Research Vision Ophthalmology Inc, v. 51, n. 8, p. 4104-4109, 2010.
ISSN 0146-0404 (Sherpa/Romeo, impact factor)
Publisher Assoc Research Vision Ophthalmology Inc
Extent 4104-4109
Origin http://dx.doi.org/10.1167/iovs.09-4716
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000280194100039
URI http://repositorio.unifesp.br/handle/11600/32752

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account